002004 华邦健康
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入2,818,703-0.08%11,512,34711,664,67011,594,59013,232,366
减:营业总成本2,516,631-0.96%10,357,70610,758,06110,449,04411,557,133
    其中:营业成本1,807,6251.90%7,261,5597,683,8597,059,5247,874,068
               财务费用74,34234.44%276,241270,037230,777207,490
               资产减值损失(3,945)-3,863.32%(185,872)(929,743)(380,091)(560,356)
公允价值变动收益(1,812)-391.12%6,6623,0971,199(4,837)
投资收益19,36852.50%60,324(172,079)7,521441,485
    其中:对联营企业和合营企业的投资收益9,083158.90%15,986(215,163)(28,839)425,722
营业利润321,9203.74%1,046,586(127,435)926,5111,645,000
利润总额320,9293.64%1,057,869(160,507)892,3881,622,696
减:所得税费用80,01616.23%176,636182,086215,456495,488
净利润240,9130.05%881,233(342,594)676,9321,127,207
减:非控股权益86,08052.47%168,045(43,604)374,810693,724
股东净利润154,832-16.01%713,188(298,990)302,122433,484

市场价值指针
每股收益 (元) *0.079-15.95%0.362-0.1510.1530.219
每股派息 (元) *----0.450--0.2200.220
每股净资产 (元) *5.2519.09%5.1624.7165.1045.148
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容